OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free INTI Stock Alerts $0.07 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.0750-Day Range$0.05▼$0.1052-Week Range$0.01▼$0.30Volume47,016 shsAverage Volume16,545 shsMarket Capitalization$12.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Inhibitor Therapeutics alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Inhibitor Therapeutics Stock (OTCMKTS:INTI)Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.Read More INTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INTI Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comPfizer (NYSE:PFE) and Inhibitor Therapeutics (OTCMKTS:INTI) Critical AnalysisMarch 14, 2024 | finance.yahoo.comJanus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future OpportunitiesMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 14, 2024 | finance.yahoo.comExploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034January 10, 2024 | seekingalpha.comiTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchJanuary 10, 2024 | tmcnet.comVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of VitiligoDecember 19, 2023 | finance.yahoo.comIntroducing Inhibitor Therapeutics, Inc. New Scientific Advisory BoardDecember 13, 2023 | finance.yahoo.comInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins UniversityMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 4, 2023 | tmcnet.comInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNovember 14, 2023 | markets.businessinsider.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNovember 7, 2023 | finance.yahoo.comCardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023October 16, 2023 | businesswire.comAntiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer TherapeuticsSeptember 5, 2023 | benzinga.comNykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical CancerMay 18, 2023 | finanznachrichten.deTrueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 18, 2023 | businesswire.comTrueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 17, 2023 | marketwatch.comCorrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030May 17, 2023 | marketwatch.comWax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030April 20, 2023 | wsj.comInhibitor Therapeutics Inc.April 4, 2023 | msn.comOncternal Therapeutics Announces Strategic Reprioritization, Stops Two Zilovertamab StudiesApril 4, 2023 | uk.finance.yahoo.comiOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical TrialMarch 31, 2023 | marketwatch.com2023-2029 Medical FLT3 Inhibitor Market Share and Growth Insights | Latest Research ReportMarch 25, 2023 | marketwatch.comNorepinephrine Reuptake Inhibitor Market Share by 2031March 24, 2023 | marketwatch.comProton Pump Inhibitor Drug Market with Latest Technology Estimate up to 2030March 24, 2023 | marketwatch.comPAA Scale Inhibitor Market Top Players By 2031February 10, 2023 | finance.yahoo.comInhibitor Therapeutics, Inc. (INTI)January 31, 2023 | finance.yahoo.comAbbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)See More Headlines Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:INTI CUSIPN/A CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$12.11 million Net MarginsN/A Pretax MarginN/A Return on Equity141.81% Return on Assets98.65% Debt Debt-to-Equity RatioN/A Current Ratio61.42 Quick Ratio61.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.07 per share Price / Cash Flow0.99 Book Value$0.05 per share Price / Book1.40Miscellaneous Outstanding Shares171,970,000Free Float164,057,000Market Cap$12.04 million OptionableNot Optionable Beta-0.81 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Francis E. O'Donnell Jr. (Age 74)M.D., Founder, Executive Chairman & CEO Comp: $600kMr. James A. McNulty CPA (Age 74)Interim CFO, Treasurer & Secretary Comp: $205.4kKey CompetitorsAgeX TherapeuticsNYSE:AGEElevai LabsNASDAQ:ELABJanOneNASDAQ:JANEterna TherapeuticsNASDAQ:ERNAMolecular TemplatesNASDAQ:MTEMView All Competitors INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed in 2024? Inhibitor Therapeutics' stock was trading at $0.0920 at the beginning of 2024. Since then, INTI stock has decreased by 23.9% and is now trading at $0.07. View the best growth stocks for 2024 here. Are investors shorting Inhibitor Therapeutics? Inhibitor Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 100 shares, a decrease of 99.6% from the February 29th total of 24,800 shares. Based on an average daily volume of 10,800 shares, the days-to-cover ratio is currently 0.0 days. View Inhibitor Therapeutics' Short Interest. When is Inhibitor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our INTI earnings forecast. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INTI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.